Layton JB, Forns J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Plain language summary of mortality rates of patients with Parkinson's disease psychosis who were treated either with pimavanserin or with different second-generation (atypical) antipsychotics. Futur Neurol. 2025 Feb 28;20(1). doi: 10.1080/14796708.2025.2463315
Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039
Hansen MK, Gammelager H, Jacobsen CJ, Hjortdal VE, Layton JB, Rasmussen BS, Andreasen JJ, Johnsen SP, Christiansen CF. Acute kidney injury and long-term risk of cardiovascular events after cardiac surgery: a population-based cohort study. J Cardiothorac Vasc Anesth. 2015 Jun;29(3):617-25. doi: 10.1053/j.jvca.2014.08.020